Safety and Survival Outcomes of<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior<sup>223</sup>Ra treatment: The RALU Study
The Journal of nuclear medicine